On September 3, 2023, MIT Lincoln Laboratory hosted a stop of the National Security Commission on Emerging Biotechnology (NSCEB) roadshow. The gathering brought together state agencies, defense centers, universities, technology firms and business leaders to discuss how Massachusetts’ biotech ecosystem can bolster national biodefense.
Christina Rudzinski, assistant head of the Biotechnology and Human Systems Division at Lincoln Laboratory, noted that the region has abundant assets to push the bio‑industrial sector beyond pharmaceuticals into a broader industrial landscape. NSCEB’s role is to link policy with the work already happening at Lincoln Laboratory and across the state.
Biotechnology touches many economic and defense domains, from disease‑resistant crops and life‑saving medicines to biofuels and advanced manufacturing materials. Congress created NSCEB in 2022 to assess the national‑security implications of this fast‑moving field and issue policy recommendations. In April 2025 the 11‑member bipartisan commission released a report calling for at least $15 billion of federal investment over five years. The report warned that China is pouring resources into the sector, echoing earlier competition in semiconductors.
Now in the final year of its three‑year mandate, NSCEB is touring the country to see local biotech ecosystems in action and bring insights back to Washington to help Congress support regional strengths.
Massachusetts has earmarked biotechnology as a priority under its Strategic Hub for Innovation, Exchange, and Leadership in Defense (SHIELD) initiative. Launched by Governor Maura Healey in October 2025 with an initial $47 million alignment investment, the program quickly rolled out the BioNexus effort, which leverages state matching funds to develop biotech and biomanufacturing solutions for the U.S. Army Combat Capabilities Development Command (DEVCOM). Healey also secured a $100 million authorization for defense‑sector capital projects in the Mass Wins Act, currently under legislative review.
During the roadshow, Ben Linville‑Engler, co‑chair of the SHIELD Working Group and deputy director of the Massachusetts Technology Collaborative, led a panel with representatives from the Massachusetts Life Sciences Center, Business Executives for National Security, Activate, DEVCOM Soldier Center, MassChallenge, Perimeter, the Center for Advanced Manufacturing and the Massachusetts AI Hub. More than 40 partner organizations now participate in SHIELD. Linville‑Engler highlighted the convergence of economic development and national security across land, air, sea, space, cyber and bio, noting the state’s $48.6 billion defense‑sector economic contribution last year.
In July the SHIELD Working Group submitted a report outlining steps to speed technology transition to deployable capabilities, strengthen the defense workforce pipeline and reinforce the state’s national‑security industrial base. Lincoln Laboratory, as a federally funded R&D center of the Department of War, possesses deep knowledge of defense needs and sustained ties to academia, industry and government labs—assets that can strengthen biotech collaborations across Massachusetts and New England.
One concrete effort is the Biotechnology Scale‑up Hub for Innovation, Economic Development, Labor Training, and Defense (BioSHIELD). Planned for Worcester, the 200,000‑square‑foot facility aims to mobilize the region’s defense‑biotech sector. Project co‑lead Edward Wack described BioSHIELD’s mission as accelerating breakthrough biomanufacturing solutions that enhance national resilience, spur commercial innovation and grow the regional economy. The hub will provide shared equipment, infrastructure and secure lab space to bridge the “valley of death” between early‑stage discovery and commercial or military‑scale production. Partners include Massachusetts Biomedical Initiatives, Worcester Polytechnic Institute, Bio Base Europe Pilot Plant and Lincoln Laboratory. A memorandum of understanding has been signed, design workshops are slated to begin soon, followed by funding and construction.
Other discussions focused on the intersection of biotechnology and artificial intelligence. Panelists from Boston University, UMass Boston, the Massachusetts Life Sciences Center, the Parker Institute for Cancer Immunotherapy, the Wyss Institute and Phicil‑itate Change examined challenges in gathering high‑quality AI‑ready datasets and opportunities for AI to improve biomanufacturing and therapeutics.
Closing the event, Wack called for continued collaboration as the nation moves at speed and scale to stay at the forefront of biotechnology.
Review